The recommended dosage of VABOMERE is 4 grams (meropenem 2 grams and vaborbactam 2 grams) administered every 8 hours by intravenous (IV) infusion over 3 hours in patients 18 years of age and older ...

Shionogi has announced positive results from the phase 3 APEKS-NP trial of cefiderocol (S-649266) for the treatment of nosocomial pneumonia.

Sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year ...

Retention times for meropenem and cefuroxime were 4.7 and 7.7 minutes, respectively. Peaks for meropenem's degradation products appeared between 1 and 2.1 minutes.

The estimated shelf life of the 20-mg/mL meropenem solution was 242 and 195 hours for the PVC and elastomeric infusion containers, respectively ( Table 2 ).

The phase 3 CERTAIN-1 study compared the efficacy and safety of cefepime-taniborbactam to meropenem in 661 adults with cUTI.

Basel, Switzerland, June 12, 2014 - Basilea Pharmaceutica Ltd. ( PK5.BE) has initiated a phase 1 clinical study with its Gram-negative antibiotic BAL30072 evaluating the safety, tolerability and ...

A novel combination that includes ceftriaxone, sulbactam and disodium EDTA, or CSE, was noninferior to meropenem for the treatment of complicated UTIs, or cUTIs, caused by extended-spectrum beta ...

In addition, we have not observed an increased risk for Gram-positive infections among patients receiving prophylaxis with meropenem, nor an increased risk of fungal infections as suggested by ...

Methods: We reported the use of meropenem in 23 neonates, gestational age of 30. to 39. weeks and birth weight of 1250 - 3100 grams with severe infections due to MDR Escherichia coli, Klebsiellae ...

Sales revenue of Meropenem in the Chinese market has an increasing trend from 2016 to 2019. In 2020, sales revenue of Meropenem in China was CNY1.88 billion, which decreased 12.2% Year on Year.